626220-76-6

Usage

Uses

Used in Pharmaceutical Research:
(R)-1-methoxypropan-2-amine hydrochloride is used as a research chemical for investigating its potential therapeutic applications in treating psychological conditions. Its psychoactive properties, including dissociation, hallucinations, and euphoria, make it a valuable tool for studying the underlying mechanisms of these conditions and developing novel treatment strategies.
Used in Drug Development:
In the pharmaceutical industry, (R)-1-methoxypropan-2-amine hydrochloride is used as a lead compound in the development of new drugs targeting specific psychological disorders. Its structural similarity to other dissociative anesthetics allows researchers to explore its potential as a therapeutic agent, with the aim of improving the safety and efficacy of existing treatments.
Used in Neuroscientific Research:
(R)-1-methoxypropan-2-amine hydrochloride is employed as a research tool in neuroscientific studies to better understand the neural mechanisms underlying the psychoactive effects of arylcyclohexylamine drugs. By examining the interactions of (R)-1-methoxypropan-2-amine hydrochloride with various neurotransmitter systems, researchers can gain insights into the pathways involved in dissociation, hallucinations, and euphoria, potentially leading to the discovery of new therapeutic targets.
Used in Toxicological Studies:
In toxicology, (R)-1-methoxypropan-2-amine hydrochloride is used to evaluate the safety and potential side effects of this class of drugs. By studying its pharmacokinetics, metabolism, and toxicological profile, researchers can assess the risks associated with its use and develop strategies to mitigate any adverse effects.
Used in Forensic Analysis:
(R)-1-methoxypropan-2-amine hydrochloride is utilized in forensic analysis to detect and identify the presence of this psychoactive substance in biological samples, such as blood or urine. This is crucial for legal purposes, particularly in cases involving drug abuse or intoxication-related incidents.

Upstream product

• 955399-15-2 [(1R)-2-methoxy-1-methylethyl]carbamic acid tert-butyl ester 
• 1381925-39-8 2-((R)-2-methoxy-1-methyl-ethyl)isoindole-1,3-dione 

Downstream Products

• 1370287-54-9 (R)-3-(4-isopropylphenyl)-N-(1-methoxypropan-2-yl)-7-methylpyrazolo[1,5-a]pyrimidine-6- 

Relevant academic research and scientific papers

THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

ISOINDOLYL COMPOUNDS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: wherein R1 is optionally substituted imidazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES

Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1 is a group of formula A or formula B; and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.